Back to results
US 7,879,859 B2Granted
Diagnosis and treatment of type 2 diabetes and other disorders
AssigneeMerck Sharp & Dohme Corp.
InventorsYun-Ping Zhou, Jing Li, Weizhen Wu, Jin Shang, John R. Thompson, Nancy A. Thornberry
Life of this patent
Estimating the term…
Abstract
The present application features the use of the somatostatin subtype 3 receptor (SST3) as a target for affecting insulin secretion and for diagnosing diabetes related disorders. Glucose stimulated insulin secretion was found to be stimulated by knocking down expression of SST3 and through the use of a SST3 selective antagonist.
Claims4
A method for increasing insulin secretion in patient in need thereof comprising the step of administering to said patient an effective amount of a somatostatin subtype 3 receptor (SST3) antagonist of Formula 1:
- wherein is R1 is selected from the group consisting of:
- wherein R2 and R3 is each independently selected from the group consisting of:
- (C1-4)alkoxy(C1-4)alkyl, (C3-7)cycloakyl(C1-4)alkyl, and, if R1 is not an optionally substituted phenyl, (C1-12)alkyl;
- R4 is selected from the group consisting of:
- hydrogen, (C1-4)alkyl, (C1-4)alkoxy, halogen, and trifluoromethyl;
- R5 is selected from the group consisting of:
- hydrogen and (C1-4)alkyl;
- R6 is (C1-4)alkyl;
- R7 and R8 is each independently selected from the group consisting of:
- hydrogen and (C1-4)alkyl;
- and
- X is selected from the group consisting of:
- hydrogen, (C1-4)alkoxy, (C1-4)alkylamino, and di(C1-4)alkylamino;
- or a pharmaceutically acceptable salt or solvate thereof.
11 more elements
Dependencies are inferred from the claim text.